Kryptos Biotechnologies develops a single-cell multinomics system that analyzes multiple analytes, including nucleic acids and proteins, to provide detailed insights into cancer cell heterogeneity. Additionally, their integrated sample-to-answer PCR molecular diagnostic system enables rapid point-of-care testing for infectious diseases, delivering results in 25 minutes with lab-level accuracy.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
OHFounders
Product
Problem
Current methods for analyzing cancer cell heterogeneity are often limited in their ability to simultaneously analyze multiple analytes within a single cell. Existing infectious disease diagnostics may lack the speed and accessibility needed for timely point-of-care testing in decentralized clinical settings.
Solution
Kryptos Biotechnologies offers two distinct solutions: a single-cell multinomics system and an integrated PCR molecular diagnostic system. The single-cell multinomics system enables researchers and clinicians to investigate multiple analytes, including nucleic acids (DNA, RNA) and proteins, within individual cells, providing comprehensive insights into complex diseases like cancer. The integrated PCR system facilitates rapid, point-of-care testing for infectious diseases, delivering sample-to-answer results in approximately 25 minutes with accuracy comparable to traditional lab-based systems. Both systems aim to provide actionable data for informed decision-making in precision medicine and infectious disease management.
Target Audience
The single-cell multinomics system targets oncologists, researchers, and pharmaceutical companies involved in precision medicine and cancer research. The infectious disease diagnostic system targets physicians and healthcare providers in decentralized clinical settings needing rapid and accurate point-of-care testing.
Features
- Single-cell multinomics system for simultaneous analysis of DNA, RNA, and protein analytes
- PCR-based technology for high sensitivity and specificity in analyte detection
- Integrated sample-to-answer system minimizing hands-on time and contamination risk
- Rapid 25-minute turnaround time for point-of-care infectious disease diagnostics
- Designed for use in decentralized clinical settings, such as clinics and on-site screening locations